同和藥業(300636.SZ):旌輝創投已於5月25日-6月12日減持1.31%的股份
格隆匯6月14日丨同和藥業(300636.SZ)公佈,公司於近日收到公司股東寧波旌輝創業投資合夥企業(有限合夥)(“旌輝創投”)出具的《減持公司股份進展告知函》。截至2020年6月12日,旌輝創投自前次公告持股變動比例達到1%後(詳見公司於2020年3月18日披露的《關於持股5%以上股東減持股份比例達到1%暨提前終止減持計劃的公告(公告編號:2020-021)》)減持公司股份比例再次超過公司總股本的1%。
旌輝創投已於2020年5月25日至2020年6月12日減持170.024萬股,減持比例1.31%。變動後持有公司股份1242.5598萬股,佔公司總股本比例9.59%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.